Terms: = Endocrine gland cancer AND JAK3, L-JAK, 3718, ENSG00000105639, P52333, JAKL, JAK-3, LJAK, JAK3_HUMAN AND Prognosis
6 results:
1. Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in Pancreatic Ductal Adenocarcinoma Microenvironment.
Yin Z; Chen S
Pancreas; 2022 Oct; 51(9):1235-1247. PubMed ID: 37078951
[TBL] [Abstract] [Full Text] [Related]
2. MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian cancer.
Jiang B; Zhu SJ; Xiao SS; Xue M
Inflammation; 2019 Oct; 42(5):1517-1529. PubMed ID: 31049770
[TBL] [Abstract] [Full Text] [Related]
3. Integrated Genomic and Immunophenotypic Classification of Pancreatic cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Wartenberg M; Cibin S; Zlobec I; Vassella E; Eppenberger-Castori S; Terracciano L; Eichmann MD; Worni M; Gloor B; Perren A; Karamitopoulou E
Clin Cancer Res; 2018 Sep; 24(18):4444-4454. PubMed ID: 29661773
[No Abstract] [Full Text] [Related]
4. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic cancer: A Systematic Review and Meta-Analysis.
Chiramel J; Backen AC; Pihlak R; Lamarca A; Frizziero M; Tariq NU; Hubner RA; Valle JW; Amir E; McNamara MG
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28445400
[TBL] [Abstract] [Full Text] [Related]
5. Screening and identification of small molecule inhibitors of ErbB2-induced invasion.
Brix DM; Rafn B; Bundgaard Clemmensen K; Andersen SH; Ambartsumian N; Jäättelä M; Kallunki T
Mol Oncol; 2014 Dec; 8(8):1703-18. PubMed ID: 25070180
[TBL] [Abstract] [Full Text] [Related]
6. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.
Ragazzon B; Libé R; Assié G; Tissier F; Barreau O; Houdayer C; Perlemoine K; Audebourg A; Clauser E; René-Corail F; Bertagna X; Dousset B; Bertherat J; Groussin L
Eur J Endocrinol; 2014 Mar; 170(3):385-91. PubMed ID: 24347427
[TBL] [Abstract] [Full Text] [Related]
